Attached files
| file | filename |
|---|---|
| EX-16.1 - EXHIBIT 16.1 - Lotus Biotech Development Corp. | form8kexhibit161template3.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 28, 2016
Lotus Biotech Development Corp.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
Nevada | 000-54745 | TBA |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
|
|
|
|
28202 N.58th Street, Cave Creek, NV | 85331 |
(Address of principal executive offices) | (Zip Code) |
|
|
Registrant’s telephone number, including area code: 480-275-2294
|
|
__________________Starflick.com_________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
|
|
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
1
SECTION 4 – MATTERS RELATED TO ACCOUNTANTS AND FINANCIALS STATEMENTS
ITEM 4.01 CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT
Filing Dated November 21, 2016
As of November 17, 2016 Malone Bailey was dismissed as the Auditor for the company. Subsequently, the 10Q filing dated November 21, 2016 has not been reviewed by an Independent Accountant and was inadvertently filed in error. The Company is actively seeking a new independent audit firm at which time the company will re-submit an amended 10Q.
The reports of Malone Bailey, on our financial statements for each of the past two fiscal years contained no adverse opinion or a disclaimer of opinion and were not modified; however, the reports were qualified as to the uncertainty of our ability to continue as a going concern due to our dependence on a successful execution of our plan of operations and ability to raise additional financing, lack of our generation of revenues, and our stockholders’ deficit and negative working capital. The decision to seek new independent accountants was approved by our sole Director on November 17, 2016.
During our two most recent fiscal years and through the date of this report, we have had no disagreements with Malone Bailey, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Malone Bailey, would have caused it to make reference to the subject matter of such disagreements in its report on our financial statements for such periods.
During our two most recent fiscal years and through the date of this report on Form 8-K, there have been no reportable events as defined under Item 304(a)(1)(v) of Regulation S-K adopted by the SEC.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) The following exhibits are filed with this report:
Exhibit No. | Document | Location |
16.1
| Letter from Malone Bailey, LLP. Dated November 28, 2016, to the Securities and Exchange Commission. | Filed herewith |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lotus Biotech Development Corp.
/s/ Michael Palethorpe
Michael Palethorpe
Chief Executive Officer
Date: November 28, 2016
3